dimanche 15 novembre 2026
RechercherExplore
fr.via.news
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· December 24, 2025

Is JPMorgan Stock a Buy for 2026 as it Hits an All-Time High?

View original at finance.yahoo.com
Is JPMorgan Stock a Buy for 2026 as it Hits an All-Time High? JPMorgan’s JPM shares reached a new all-time high of $327.78 yesterday, driven by optimism for the easing rate cycle and stronger U.S…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Consensus mark for 2025 and 2026 revenues suggests a year-over-year rise of 2.8% and 3.9%, respectively

    80% confidence

  • JPMorgan remains well-placed for growth in 2026, backed by its robust capital markets business, dominant IB position, decent NII growth expectations and continued expansion through branch openings

    80% confidence

  • NII expected to rise 6-7% in 2025

    80% confidence

  • JPMorgan is mulling entry into the crypto trading business

    80% confidence

  • 2026 non-interest expenses expected to rise by more than $9 billion to $105 billion

    80% confidence

  • NII (excluding Markets) expected to grow 5.5%

    80% confidence

  • NII (excluding Markets) expected to be nearly $92.2 billion in 2025 and $95 billion in 2026

    80% confidence

  • Zacks Consensus Estimate for earnings implies 2.9% and 3.5% year-over-year growth for 2025 and 2026, respectively

    80% confidence
Ce que nous savons · l'intelligence derrière cette page
En direct du substrat
Ce que nous observons
Q4 2026 Biotech Catalyst Cluster: Late-Stage Data and PDUFA Dates Converge
Early-to-mid November 2026 is a dense run of clinical readouts and Q3 earnings at AHA, AASLD, ACR and ASH. Mid-cap biotechs (Vir, Mineralys, Arrowhead, Oryzon, Novartis, J&J) are reporting data that feeds into regulatory decisions. The next ones are the ivonescimab BLA (Nov 14) and the lorundrostat PDUFA (Dec 22), followed by ECLIPSE 2/3 and Maritime-1 readouts in Q1 2027. The list also includes an unrelated delisting track (EGM Nov 19, application Jan 25, 2027), and the facts have no AI or fintech content.
Notre lecture des données ›
Signaux que nous suivons
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Tendances que nous surveillons ›
Là où les sources divergent
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Nous signalons les conflits ouvertement ›
Vérifié récemment
✓ Vérifié avec la source d'origine
4,997
faits reliés à leur source, et nous signalons ceux qui ne tiennent pas.
101 entités suivies4,997 faits vérifiés avec la source5,585 documents sources archivés
Interrogez ces données → isubstrate.com
Is JPMorgan Stock a Buy for 2026 as it Hits an All-Time High?: Source | Via News | fr.via.news